Amakem Appoints Dr. Steve Pakola as Chief Medical Officer
Dr. George Lasezkay Joins Board of Directors
Dr. Pakola was previously Chief Medical Officer at ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, where he played a pivotal role in driving the development of ThromboGenics’ lead product, ocriplasmin, from initial concept through to regulatory submission.
Dr. Lasezkay was previously Corporate Vice President of Corporate Development and Assistant General Counsel for Allergan, Inc., a global pharmaceutical and medical aesthetics company. In these positions, he was responsible for corporate strategy as well as licensing, R&D collaboration and acquisition transactions involving both products and companies. George is currently an industry consultant and serves as an advisor to a number of public and private biotechnology companies developing therapies for ophthalmic conditions.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.